Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.39 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 362,114 shares.
Wall Street Analyst Weigh In
ATOS has been the subject of a number of research reports. Ascendiant Capital Markets upped their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Atossa Therapeutics in a research note on Monday, August 12th. Finally, StockNews.com lowered Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, August 12th.
Get Our Latest Stock Analysis on ATOS
Atossa Therapeutics Price Performance
The company has a market capitalization of $188.64 million, a PE ratio of -6.25 and a beta of 1.20. The firm's 50 day moving average is $1.41 and its 200 day moving average is $1.39.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, analysts predict that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Atossa Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in Atossa Therapeutics in the 2nd quarter worth $29,000. SG Americas Securities LLC lifted its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the period. Cetera Advisors LLC bought a new stake in Atossa Therapeutics during the 1st quarter valued at approximately $72,000. Vanguard Group Inc. grew its holdings in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock worth $10,357,000 after acquiring an additional 78,269 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Atossa Therapeutics in the 1st quarter worth approximately $151,000. Institutional investors own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Read More
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
